ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Anticoagulant agent: Fibrinolytic enzyme
173-L-Serine-174-L-tyrosine-175-L-glutamine-173-527-plasminogen activator (human tiβue-type)
Recombinant human tissue plasminogen activator (rt-PA)
- Reteplasum (Latin)
- Reteplase (German)
- Reteplase (French)
- Reteplasa (Spanish)
- Reteplase (OS: BAN, USAN)
- BM 06022 (IS: Boehringer Mannheim)
- r-PA (IS)
- Pai Tong Xin
IND Pharma, China
Actavis, United Arab Emirates; Actavis, Australia; Actavis, Bosnia & Herzegowina; Actavis, Bahrain; Actavis, Germany; Actavis, Denmark; Actavis, France; Actavis, Greece; Actavis, Hong Kong; Actavis, Kuwait; Actavis, Lithuania; Actavis, Netherlands; Actavis, Oman; Actavis, Portugal; Actavis, Qatar; Actavis, Romania; Actavis, Saudi Arabia; Actavis, Sweden; Actavis, Turkey; Actavis, Yemen; Actavis Group, Austria; Actavis Group, Spain; Actavis Group, Poland; Actavis Italy, Italy; Actavis UK, United Kingdom; Actavis Group, Iceland
Centocor, United States
- Rui Tong Li
Ahua Pharmaceutical, China
|BAN||British Approved Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.